WallStSmart

Merck & Company Inc (MRK)vsSemler Scientific Inc (SMLR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 152927% more annual revenue ($65.77B vs $42.98M). MRK leads profitability with a 13.6% profit margin vs 0.9%. SMLR trades at a lower P/E of 5.0x. SMLR earns a higher WallStSmart Score of 53/100 (C-).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

SMLR

Buy

53

out of 100

Grade: C-

Growth: 5.3Profit: 3.5Value: 8.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued
SMLRUndervalued (+37.1%)

Margin of Safety

+37.1%

Fair Value

$32.33

Current Price

$20.33

$12.00 discount

UndervaluedFair: $32.33Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

SMLR3 strengths · Avg: 10.0/10
P/E RatioValuation
5.0x10/10

Attractively priced relative to earnings

Price/BookValuation
0.8x10/10

Reasonable price relative to book value

EPS GrowthGrowth
3570.1%10/10

Earnings expanding 3570.1% YoY

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

SMLR4 concerns · Avg: 2.8/10
Market CapQuality
$348.27M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.2%3/10

ROE of 0.2% — below average capital efficiency

Profit MarginProfitability
0.9%3/10

0.9% margin — thin

Revenue GrowthGrowth
-0.4%2/10

Revenue declined 0.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : SMLR

The strongest argument for SMLR centers on P/E Ratio, Price/Book, EPS Growth.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : SMLR

The primary concerns for SMLR are Market Cap, Return on Equity, Profit Margin. Thin 0.9% margins leave little buffer for downturns.

Key Dynamics to Monitor

SMLR carries more volatility with a beta of 1.33 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SMLR scores higher overall (53/100 vs 50/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Semler Scientific Inc

HEALTHCARE · MEDICAL DEVICES · USA

Semler Scientific, Inc. develops, manufactures, and markets proprietary products that help healthcare providers evaluate and treat patients with chronic conditions in the United States. The company is headquartered in Santa Clara, California.

Want to dig deeper into these stocks?